Meeting Highlights
Miami, March 27, 2009
Maui, January 14-17, 2009
San Francisco, October 24-29, 2008
Paris, June 11-14, 2008
Chicago, April 10, 2008
San Francisco, March 5-9, 2008
Boston, November 6-11, 2007
Honolulu, September 14-19, 2007
Barcelona, June 13-16, 2007
Arthritis News
Thursday, July 02, 2009
Lung Study Questions Leflunomide Safety in RA
Rheumatologists who routinely use leflunomide in rheumatoid arthritis patients should be on the look-out for early signs of lung disease...
Wednesday, July 01, 2009
Masitinib Pilot Study Shows Promise in DMARD-resistant RA
The first drug to target mast cells in RA shows promising early results in an uncontrolled phase 2a trial...
Friday, June 26, 2009
Gum Disease Prominent in RA, but TNF-Blockade Can Help
Three new studies shed light on the connection between rheumatoid arthritis (RA) and periodontitis, and new data help define a role for TNF-blockade in improving periodontal status as well as RA signs and symptoms...
Thursday, June 25, 2009
Pegloticase Shrinks Tophi Even in Resistant Gout
Pegloticase significantly reduced tophus size in 40% of treatment-failure gout patients...
Wednesday, June 24, 2009
RA Rituxan Response Seen Best with High Res US
High resolution grey-scale ultrasonography may help rheumatologists measure response to rituximab treatment in rheumatoid arthritis (RA) patients...
Monday, June 22, 2009
IL-Blockade with Canakinumab Effective, Safe in JIA
Phase II data show that canakinumab (ACZ885) seems effective and safe in children with systemic juvenile idiopathic arthritis...
Monday, June 22, 2009
EULAR Studies Show New Picture of B-Cell Depletion in RA
A group of studies reported at EULAR show that B-cell depletion is a relatively safe and effective treatment option for patients with rheumatoid arthritis (RA)...
Wednesday, June 17, 2009
EULAR Report Shows Tocilizumab Protects Joints in RA
Actemra® maintained structure and function in a wide range of RA patients in the LITHE study, with response durations of 2 years in interim analyses...
Tuesday, June 16, 2009
Golimumab for Psoriatic Arthritis Still Effective at 2 Years
2-Year GO-REVEAL data show durable PsA response to golimumab...
Thursday, June 11, 2009
RA Bone Changes May Offer New Treatment Target
Osteoporosis and erosions appear loosely linked in some RA patients...





